156 results match your criteria Injectable Bulking Agents for Incontinence


Gastrointestinal dysfunction in movement disorders.

Authors:
Ryuji Sakakibara

Neurol Sci 2021 Apr 4;42(4):1355-1365. Epub 2021 Feb 4.

Sakura Medical Center, Toho University, 564-1 Shimoshizu, Sakura, 285-8741, Japan.

Purpose Of Review: This article provides an overview of the clinical presentation, investigations, and treatment options for gastrointestinal tract (GIT) dysfunction in patients with Parkinson's disease (PD) and other movement disorders.

Recent Findings: GIT dysfunction commonly appears as constipation and fecal incontinence (mostly overflow, accompanied with sphincter failure in multiple system atrophy [MSA]). Bowel dysfunction (underactive) occurs irrespectively from the site of the neurologic lesion, which is in contrast to site-dependent bladder dysfunction (brain, overactive; periphery, underactive). Read More

View Article and Full-Text PDF

Seven-year efficacy and safety outcomes of Bulkamid for the treatment of stress urinary incontinence.

Neurourol Urodyn 2021 01 7;40(1):502-508. Epub 2021 Jan 7.

Section of Urogynecology and Pelvic Reconstructive Surgery, Stanford University School of Medicine, Stanford, California, USA.

Aims: Bulking agents are a minimally invasive treatment option for women with stress urinary incontinence (SUI) or stress-predominant mixed urinary incontinence (MUI). The aim of this study was to evaluate long-term efficacy and safety following treatment with Bulkamid as a primary procedure for SUI or stress-predominant MUI.

Methods: This was an Institutional Review Board-approved single-center retrospective study of female patients with SUI or stress-predominant MUI who had undergone injection with Bulkamid since 2005 and had completed 7 years of follow up. Read More

View Article and Full-Text PDF
January 2021

Use of bioactive extracellular matrix fragments as a urethral bulking agent to treat stress urinary incontinence.

Acta Biomater 2020 11 6;117:156-166. Epub 2020 Oct 6.

Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Eastern Institute of Urologic Reconstruction, Shanghai Jiao Tong University, Shanghai 200233, China. Electronic address:

Injection of urethral bulking agents is a low-risk, minimally invasive surgical procedure to treat stress urinary incontinence (SUI). In this study, we developed a promising injectable bulking agent comprising extracellular matrix fragments of adipose-derived stem cell sheets (ADSC ECM) and investigated its effectiveness in urethral bulking therapy. The structural integrity and proteins of ADSC sheet ECM were well retained in decellularized ADSC ECM fragments. Read More

View Article and Full-Text PDF
November 2020

Artificial urinary sphincter: current status and future directions.

Authors:
Culley C Carson

Asian J Androl 2020 Mar-Apr;22(2):154-157

Department of Urology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.

Urge urinary incontinence (UUI) is one of the most troublesome complications of surgery of the prostate whether for malignancy or benign conditions. For many decades, there have been attempts to reduce the morbidity of this outcome with variable results. Since its development in the 1970s, the artificial urinary sphincter (AUS) has been the "gold standard" for treatment of the most severe cases of UUI. Read More

View Article and Full-Text PDF
February 2021

Management of erectile dysfunction and LUTS/incontinence: the two most common, long-term side effects of prostate cancer treatment.

Can J Urol 2020 02;27(27 Suppl 1):17-24

Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.

The two major long-term concerns associated with different options for the management of prostate cancer, (including surgery, radiotherapy, brachytherapy, cryotherapy, HIFU, etc.) include difficulties with lower urinary tract symptoms (LUTS) and/or erectile dysfunction. LUTS can be in the form of stress urinary incontinence (SUI), urge urinary incontinence (UUI), frequency/urgency, and/or voiding difficulties. Read More

View Article and Full-Text PDF
February 2020

Lower Urinary Tract and Bowel Dysfunction in Neurologic Disease.

Continuum (Minneap Minn) 2020 02;26(1):178-199

Purpose Of Review: This article provides an overview of the clinical presentation, investigations, and treatment options for lower urinary tract and bowel dysfunction in patients with neurologic diseases.

Recent Findings: The site of the neurologic lesion influences the pattern of lower urinary tract dysfunction. Antimuscarinic agents are first-line management for urinary incontinence; however, the side effect profile should be considered when prescribing them. Read More

View Article and Full-Text PDF
February 2020

Middle-term Outcomes of Gatekeeper Implantation for Fecal Incontinence.

Dis Colon Rectum 2020 04;63(4):514-519

Department of Medical, Surgical, Neurologic, Metabolic and Aging Sciences, General, Mini-invasive and Obesity Surgery Unit, University of Campania "Luigi Vanvitelli," Naples, Italy.

Background: Intersphincteric injectable bulking agents are one of the current treatment options for fecal incontinence, failing behavioral and medical therapy. Gatekeeper showed promising short-term results, but long-term outcomes are unknown.

Objective: The purpose of this study was to clinically evaluate a prospective cohort of fecal incontinence patients up to 36 months after implantation of Gatekeeper. Read More

View Article and Full-Text PDF

Regenerative medicine and injection therapies in stress urinary incontinence.

Nat Rev Urol 2020 03 23;17(3):151-161. Epub 2020 Jan 23.

Royal Hallamshire Hospital, Glossop Road, Sheffield, UK.

Stress urinary incontinence (SUI) is a common and bothersome condition. Anti-incontinence surgery has high cure rates, but concerns about mesh tapes have resulted in the resurgence of surgical procedures that involve increased abdominopelvic dissection and morbidity. Injection therapy with urethral bulking agents or stem cell formulations have been developed as minimally invasive alternatives. Read More

View Article and Full-Text PDF

Urinary Incontinence in Women: Evaluation and Management.

Am Fam Physician 2019 09;100(6):339-348

Winn Army Community Hospital, Fort Stewart, GA, USA.

Urinary incontinence is a common problem among women worldwide, resulting in a substantial economic burden and decreased quality of life. The Women's Preventive Services Initiative is the only major organization that recommends annual screening for urinary incontinence in all women despite low to insufficient evidence regarding effectiveness and accuracy of methods. No other major organization endorses screening. Read More

View Article and Full-Text PDF
September 2019

The use of urethral bulking injections in post-prostatectomy stress urinary incontinence: A narrative review of the literature.

Neurourol Urodyn 2019 11 20;38(8):2060-2069. Epub 2019 Aug 20.

Department of Urology, St George's NHS Foundation Trust, London, UK.

Aims: Post-prostatectomy stress urinary incontinence (PPI) is a common condition with significant impact on patient quality of life. With rising numbers of prostatectomies performed, recognition of incontinence during survivorship care is growing. With increasing hesitance of the use of suburethral mesh in females, urethral bulking injections in this patient population as a minimally invasive alternative to surgery are evaluated. Read More

View Article and Full-Text PDF
November 2019

Effectiveness of Autologous Fat Graft in Treating Fecal Incontinence.

Ann Coloproctol 2019 Jun 30;35(3):144-151. Epub 2019 Jun 30.

Department of Surgery, Busan Hangun Hospital, Busan, Korea.

Purpose: The most common risk factor for fecal incontinence (FI) is obstetric injury. FI affects 1.4%-18% of adults. Read More

View Article and Full-Text PDF

Complications of urethral bulking therapy for female stress urinary incontinence.

Neurourol Urodyn 2019 08 8;38 Suppl 4:S12-S20. Epub 2019 May 8.

Department of Urology, University of Illinois at Chicago (UIC), Chicago, Illinois.

Aims: To review, report, and discuss the complications associated with urethral bulking therapy in female stress urinary incontinence.

Methods: An extensive nonsystematic literature review on complications associated with injectable bulking agents used in the clinical practice was conducted. We reviewed articles published in English and indexed in the PubMed, Embase, and Google Scholar databases. Read More

View Article and Full-Text PDF

Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence.

Neurourol Urodyn 2019 02 4;38(2):825-837. Epub 2018 Dec 4.

Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.

Urinary incontinence is a prevalent condition worldwide and causes a tremendous impact on a woman's quality of life. While conservative and non-surgical therapies are options for treatment, surgery for stress urinary incontinence (SUI) is common. Options include colposuspension, slings (pubovaginal and midurethral), and periurethral bulking. Read More

View Article and Full-Text PDF
February 2019

Injection of Urethral Bulking Agents.

Urol Clin North Am 2019 Feb;46(1):1-15

Urinary Tract and Pelvic Reconstruction, Department of Urology, MD Anderson Cancer Center, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

Urethral injection is a safe and minimally invasive method of treating female stress urinary incontinence with multiple bulking agents currently commercially available. Although there are numerous studies that demonstrate efficacy, long-term success is not yet proven. This article aims to describe the mechanism of action and properties of various agents, patient selection factors, available techniques for injection, outcomes of urethral injections, and complications associated with the procedure. Read More

View Article and Full-Text PDF
February 2019

Can Urethral Bulking Agents Salvage Failed Slings?

Urology 2019 Feb 7;124:78-82. Epub 2018 Nov 7.

Michigan Medicine University of Michigan, Ann Arbor, MI.

Objective: To evaluate the efficacy of urethral bulking agents for stress urinary incontinence (SUI) in the setting of prior failed sling.

Methods: This is a retrospective review of patients who underwent urethral bulking agent injections for a primary complaint of SUI following prior failed sling surgery. The outcomes assessed were patient reported improvement, need for further interventions for incontinence and validated questionnaires. Read More

View Article and Full-Text PDF
February 2019

Retrospective analysis after endoscopic urethral injections of glutaraldehyde-cross-linked-collagen or dextranomer/hyaluronic acid copolymer in bitches with urinary incontinence.

J Small Anim Pract 2019 Feb 2;60(2):96-101. Epub 2018 Nov 2.

EVIDENSIA Tierärztliche Klinik für Kleintiere Norderstedt GmbH, 22850 Norderstedt, Germany.

Objectives: To evaluate the outcome of endoscopic injection of two different bulking agents, glutaraldehyde cross-linked collagen and dextranomer/hyaluronic acid copolymer into the urethral submucosa in female dogs with urinary incontinence caused by urethral sphincter mechanism incompetence.

Materials And Methods: Retrospective review of records and follow-up communication with owners of dogs that received an endoscopically guided urethral bulking procedure. In each dog, either cross-linked collagen (2007 to 2011) or dextranomer/hyaluronic acid copolymer (2012 to 2015) was used. Read More

View Article and Full-Text PDF
February 2019

Efficacy and safety of polydimethylsiloxane injection (Macroplastique ) for the treatment of female stress urinary incontinence: results of a series of 85 patients with ≥3 years of follow-up.

BJU Int 2019 02 16;123(2):353-359. Epub 2018 Oct 16.

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Objective: To assess the long-term efficacy and safety of polydimethylsiloxane injection (Macroplastique , Cogentix Medical, Orangeburg, New York, USA) for the treatment of female stress urinary incontinence (SUI), with a minimum follow-up of 3 years.

Patients And Methods: This is an observational analytical prospective cohort study conducted in a single uro-gynaecological unit. All consecutive women with urodynamically confirmed pure SUI treated with the Macroplastique procedure, were included. Read More

View Article and Full-Text PDF
February 2019

Urolastic®, a new bulking agent for treatment of stress urinary incontinence: a systematic review and meta-analysis.

Int Urogynecol J 2018 09 23;29(9):1239-1247. Epub 2018 Jun 23.

Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100, Sassari, Italy.

Introduction And Hypothesis: The aim of the present systematic review and meta-analysis was to assess the effectiveness and safety of injections of the new bulking agent Urolastic® in the treatment of patients with stress urinary incontinence (SUI).

Methods: A systematic search was carried out to select observational and experimental studies on Urolastic® in female patients with SUI. Three different databases, Pubmed, the Cochrane Central Register of Controlled Trials, and Scopus, were used to retrieve scientific articles published from their inception to 31 January 2018. Read More

View Article and Full-Text PDF
September 2018

CT and MR Imaging Features of Artificial Urinary Sphincters, Penile Prostheses, and Other Devices in the Male Lower Genitourinary Tract.

Radiographics 2018 May-Jun;38(3):794-805

From PENRAD Imaging and Colorado Springs Radiologists, Colorado Springs, Colo (E.T.C.); and Departments of Radiology (P.R., E.S.S.) and Urology (W.I.J.), Hospital of the University of Pennsylvania, 3400 Spruce St, MRI 1 Founders, Philadelphia, PA 19104-4283.

Urinary incontinence and erectile dysfunction are relatively common conditions in the aging male population. Surgical interventions for urinary incontinence include placement of an artificial urinary sphincter (AUS), perineal sling, or sacral nerve stimulator and injections of periurethral bulking agents. Erectile dysfunction can be treated surgically with placement of a penile prosthesis. Read More

View Article and Full-Text PDF
October 2018

Face, Content, and Construct Validations of Endoscopic Needle Injection Simulator for Transurethral Bulking Agent in Treatment of Stress Urinary Incontinence.

J Surg Educ 2018 Nov 3;75(6):1673-1678. Epub 2018 May 3.

Department of Urology, Division of Female Urology, Pelvic Reconstruction Surgery & Voiding Dysfunction University of California, Irvine, California. Electronic address:

Introduction And Objectives: Endoscopic injection of urethral bulking agents is an office procedure that is used to treat stress urinary incontinence secondary to internal sphincteric deficiency. Validation studies important part of simulator evaluation and is considered important step to establish the effectiveness of simulation-based training. The endoscopic needle injection (ENI) simulator has not been formally validated, although it has been used widely at University of California, Irvine. Read More

View Article and Full-Text PDF
November 2018

Achieving urinary continence in cloacal exstrophy: The surgical cost.

J Pediatr Surg 2018 Oct 24;53(10):1937-1941. Epub 2018 Feb 24.

Robert D. Jeffs Division of Pediatric Urology, The James Buchanan Brady Urological Institutions, The Johns Hopkins Hospital, Johns Hopkins Medical Institutions, Charlotte Bloomberg Children's Hospital, Baltimore, MD, USA. Electronic address:

Introduction: Cloacal exstrophy (CE) is a severe midline congenital abnormality that requires numerous surgical corrections to achieve an acceptable quality of life. Candidates for urinary continence undergo multiple procedures, most often continent bladder diversions, to become socially dry. Here, the authors investigate the number of genitourinary interventions that patients with CE undergo to attain urinary continence. Read More

View Article and Full-Text PDF
October 2018

Does intraoperative success predict outcome in the treatment of urethral sphincter insufficiency with bulking agent?

J Pediatr Urol 2018 04 31;14(2):173.e1-173.e5. Epub 2018 Jan 31.

Department of Pediatric Surgery, Children's Hospital, University of Helsinki, Helsinki, Finland. Electronic address:

Introduction: Sphincter insufficiency is mostly associated with neurogenic and some structural abnormalities in the pediatric population. As a mini-invasive treatment, urethral bulking agents have been used to treat this problem.

Objective: The aim was to evaluate if technical success, defined as intraoperative increase in abdominal leak point pressure (ALPP), predicts the outcome of the treatment of sphincter insufficiency with urethral bulking agent. Read More

View Article and Full-Text PDF

Microfluidic production of bioactive fibrin micro-beads embedded in crosslinked collagen used as an injectable bulking agent for urinary incontinence treatment.

Acta Biomater 2018 02 29;67:156-166. Epub 2017 Nov 29.

Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland. Electronic address:

Endoscopic injection of bulking agents has been widely used to treat urinary incontinence, often due to urethral sphincter complex insufficiency. The aim of the study was to develop a novel injectable bioactive collagen-fibrin bulking agent restoring long-term continence by functional muscle tissue regeneration. Fibrin micro-beads were engineered using a droplet microfluidic system. Read More

View Article and Full-Text PDF
February 2018

Effectiveness of Bulking Agent (Solesta) Therapy in Fecal Incontinence in Patients Refractory to Conventional Therapies.

Am J Med Sci 2017 11 5;354(5):476-479. Epub 2017 Sep 5.

Division of Gastroenterology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine, El Paso, Texas. Electronic address:

Background: Fecal incontinence is a problem that imposes considerable socioeconomic consequences. Despite many medical therapies, unmet needs remain. A new treatment option is a biocompatible bulking agent (Solesta) administered by submucosal injection in the distal rectum. Read More

View Article and Full-Text PDF
November 2017

Complications of Urethral Bulking Agents for Stress Urinary Incontinence: An Extensive Review Including Case Reports.

Female Pelvic Med Reconstr Surg 2018 Nov/Dec;24(6):392-398

Department of Urology, University of Illinois, Chicago, IL.

Objectives: Stress urinary incontinence in women is a common problem that significantly impacts quality of life. Periurethral injection of urethral bulking agents (UBAs) is a simple, noninvasive, and cost-effective treatment. However, complications associated with UBA are often underappreciated. Read More

View Article and Full-Text PDF

Urethral injection therapy for urinary incontinence in women.

Cochrane Database Syst Rev 2017 07 25;7:CD003881. Epub 2017 Jul 25.

Department of Urology, Sunderland Royal Hospital, Kayll Road, Sunderland, Tyne & Wear, UK, SR4 7TP.

Background: Urinary incontinence imposes a significant health and economic burden to society. Periurethral or transurethral injection of bulking agents is a minimally invasive surgical procedure used as one the surgical treatments of stress urinary incontinence (SUI) in adult women.

Objectives: To assess the effects of periurethral or transurethral injection therapy on the cure or improvement of urinary incontinence in women. Read More

View Article and Full-Text PDF

Radiographic Misdiagnoses After Periurethral Bulking Agents.

Female Pelvic Med Reconstr Surg 2018 Jul/Aug;24(4):312-314

William Beaumont School of Medicine, Oakland University, Rochester, MI.

Objectives: Injectable urethral bulking agents are commonly used to manage stress urinary incontinence. Urologic or other symptoms may prompt pelvic imaging at a later date, when bulking agents may be visualized and incorrectly interpreted. Our goal was to evaluate the incidence of misdiagnosis and which pathologies were the most common misinterpretations and their frequency. Read More

View Article and Full-Text PDF

Periurethral bulking agents for female stress urinary incontinence in Canada.

Can Urol Assoc J 2017 Jun;11(6Suppl2):S152-S154

Section of Urology, Department of Surgery, University of Calgary, Calgary, AB, Canada.

Urethral bulking aims to improve urethral mucosal coaptation, and thus outlet resistance, in an effort to limit stress-induced leakage. While efforts have been made to employ bulking agents to treat stress urinary incontinence (SUI) for more than 100 years, we remain wanting for the perfect injectable. Regardless of the agent studied, efficacy is modest at best, repeat injections are the norm, and long-term followup is conspicuously lacking. Read More

View Article and Full-Text PDF

Management of patients with stress urinary incontinence after failed midurethral sling.

Can Urol Assoc J 2017 Jun;11(6Suppl2):S143-S146

Department of Urology, Dalhousie University, Halifax, NS; Canada.

Surgical failure rates after midurethral sling (MUS) procedures are variable and range from approximately 8-57% at five years of followup. The disparity in long-term failure rates is explained by a lack of long-term followup and lack of a clear definition of what constitutes failure. A recent Cochrane review illustrates that no high-quality data exists to recommend or refute any of the different management strategies for recurrent or persistent stress urinary incontinence (SUI) after failed MUS surgery. Read More

View Article and Full-Text PDF